C.H. Boehringer Sohn AG & Co. KG
Climate Impact & Sustainability Data (2020, 2023)
Reporting Period: 2020
Environmental Metrics
Total Carbon Emissions:Not disclosed
Scope 1 Emissions:Not disclosed
Scope 2 Emissions:Not disclosed
Scope 3 Emissions:Not disclosed
Renewable Energy Share:Not disclosed
Total Energy Consumption:Not disclosed
Water Consumption:Not disclosed
Waste Generated:Not disclosed
Carbon Intensity:Not disclosed
ESG Focus Areas
- More Health
- More Potential
- More Green
Environmental Achievements
- Launched "BE GREEN – Future by Choice" program with global goals for 2030, focusing on reducing CO2 emissions, using renewable energy, reducing waste, and creating environmentally friendly products.
- Xochimilco (Mexico) production facility received Alliance Water Stewardship (AWS) certification.
Social Achievements
- Established the "Angels Initiative" to optimize stroke care, creating a network of over 4,300 clinics worldwide.
- Launched the "LastMile" initiative to improve access to veterinary medicine in sub-Saharan Africa, including a new mobile app for better management and data collection.
- Making More Health (MMH) initiative reached approximately 9.3 million people worldwide.
- Published and executed the first action plan in Germany for implementation of the UN Convention on the Rights of Persons with Disabilities 2012-2020.
- Enabled all employees to take up to 10 days of fully paid leave to volunteer with external organizations in the fight against COVID-19.
Governance Achievements
- Not disclosed
Climate Goals & Targets
Long-term Goals:
- Not disclosed
Medium-term Goals:
- Not disclosed
Short-term Goals:
- Not disclosed
Environmental Challenges
- COVID-19 pandemic impacting global economic output, trade, and investment.
- Price pressure for pharmaceuticals in core markets.
- Increased efforts to shift payment burden onto patients.
- Protection of intellectual property under pressure.
- COVID-19-related logistical challenges impacting production and supply chains.
- Declining sales in some livestock segments due to COVID-19 measures.
- Production and supply bottlenecks due to COVID-19 pandemic.
Mitigation Strategies
- Implemented measures to minimize the impact of the COVID-19 pandemic on employees, patients, and society.
- Safeguarded production and supply of medicines and veterinary pharmaceuticals.
- Expanded digital customer relations strategies.
- Implemented risk-mitigating measures to counter COVID-19-specific threats to production activities (physical segregation of teams, mask mandates, increased disinfectant supply, employee testing, work-from-home options).
- Implemented measures to guarantee reliable and high-quality supplies for internal and external customers.
- Built up internal standby capacities.
Supply Chain Management
Supplier Audits: Not disclosed
Responsible Procurement
- Not disclosed
Climate-Related Risks & Opportunities
Physical Risks
- Not disclosed
Transition Risks
- Not disclosed
Opportunities
- Not disclosed
Reporting Standards
Frameworks Used: Null
Certifications: ISO 14001, ISO 45001, ISO 50001, Alliance Water Stewardship (AWS)
Third-party Assurance: Not disclosed
UN Sustainable Development Goals
- Not disclosed
Not disclosed
Sustainable Products & Innovation
- Not disclosed
Awards & Recognition
- Top Employer award from the Top Employers Institute in multiple countries.
Reporting Period: 2023
Environmental Metrics
Renewable Energy Share:70%
ESG Focus Areas
- Health Equity
- Environmental Sustainability
- Social Responsibility
- Governance
Environmental Achievements
- Achieved carbon neutrality certification at multiple sites.
- Increased renewable electricity purchased worldwide to over 70%.
- Dortmund production site achieved "Zero Waste to Landfill" certification.
- Reduced packaging waste at Yamagata production site.
Social Achievements
- Expanded access to healthcare for over 29,000 people through the "Access to Healthcare" initiative.
- Reached over 400,000 children through the FAST Heroes program.
- Supported over 130 social entrepreneurs worldwide through the "Making More Health" initiative.
- 8,625 employees volunteered.
Governance Achievements
- Implemented a multi-layered governance structure for Human Rights.
- Published the first Human Rights Policy Statement.
- Implemented a new third-party risk management process to address Human Rights in the supply chain.
Climate Goals & Targets
Long-term Goals:
- Provide 500 million rabies vaccine doses and educate 15 million children by 2038.
Medium-term Goals:
- Become carbon neutral in company operations (Scope 1 and 2) by 2030.
- Cut resource footprint by half across the value chain by 2030.
- 100% of R&D projects and products to apply eco-design and green chemistry principles by 2030.
Short-term Goals:
- Train 2,000 employees to become health and wellbeing ambassadors by 2025.
Environmental Challenges
- High inflation rates leading to higher energy and production costs.
- Increasing global institutional efforts to lower the prices of medicinal products.
- Increasing cost burden on the healthcare system.
- Geopolitical tensions and conflicts.
Mitigation Strategies
- Implemented measures to accelerate response to changes, reduce organizational complexity, and optimize cost base.
- Strategic supplier engagement to reduce Scope 3 emissions.
- Investing in R&D to drive growth and new product flow.
- Continuous monitoring and adjustment of costs and business processes.
Supply Chain Management
Responsible Procurement
- Supplier Code of Conduct
- PSCI principles
Climate-Related Risks & Opportunities
Physical Risks
- Natural disasters
Transition Risks
- Regulatory changes
- Market shifts
Opportunities
- Development of sustainable medicines and technologies
Reporting Standards
Frameworks Used: UN Sustainable Development Goals
Certifications: Carbon Neutral Certification, Zero Waste to Landfill Certification, EcoVadis Silver Medal
UN Sustainable Development Goals
- Goal 3: Good Health and Well-being
- Goal 13: Climate Action
Initiatives contribute to these goals through improved access to healthcare, reduced environmental footprint, and social engagement.
Sustainable Products & Innovation
- SENVELGO®
- NEXGARD® PLUS
- NEXGARD® COMBO
Awards & Recognition
- German Sustainability Award
- EcoVadis Silver Medal
- Prix Galien USA Best Orphan/Rare Diseases Solution Award